Compounds > vitamin k 2
Page last updated: 2024-12-08

vitamin k 2

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID9951605
CHEMBL ID261696
SCHEMBL ID571907
SCHEMBL ID8709976
MeSH IDM0022807
PubMed CID5280374
CHEMBL ID263382
SCHEMBL ID416517
MeSH IDM0022807

Synonyms (27)

Synonym
menaquinone-3
mk-3
menaquinone(3)
CHEMBL261696
SCHEMBL571907
SCHEMBL8709976
gtpl2771
BSPBIO_001180
BPBIO1_001298
AB00514047
C00828
PRESTWICK3_001100
menaquinone-2
mk-2
menaquinone(2)
CHEMBL263382
2-(3,7-dimethylocta-2,6-dienyl)-3-methylnaphthalene-1,4-dione
HMS2098K22
2-(3,7-dimethyl-2,6-octadienyl)-3-methyl-1,4-naphthoquinone
1,4-naphthoquinone, 2-(3,7-dimethyl-2,6-octadienyl)-3-methyl-
1163-13-9
AKOS015899893
SCHEMBL416517
PTWSIIUEOFZCHW-NTCAYCPXSA-N
7421-23-0
2-[(2e)-3,7-dimethylocta-2,6-dienyl]-3-methyl-naphthalene-1,4-dione
2-[(2e)-3,7-dimethylocta-2,6-dienyl]-3-methyl-1,4-naphthoquinone
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (3)

PathwayProteinsCompounds
respiration (anaerobic)026
pyruvate fermentation to propionate I015
heme biosynthesis from uroporphyrinogen-III II012

Bioassays (17)

Assay IDTitleYearJournalArticle
AID608159Agonist activity at human FLAG-tagged SXR ligand binding domain expressed in human HepG2 cells co-transfected with pGVP2-Gal4 vector assessed as induction of CYP3A4 gene expression at 5 x 10'-6 M after 48 hrs by dual-luciferase reporter gene assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Synthesis of new vitamin K analogues as steroid and xenobiotic receptor (SXR) agonists: insights into the biological role of the side chain part of vitamin K.
AID605759Binding affinity to human SXR transfected in human HepG2 cells coexpressing GAL4 assessed as transcriptional activation at 5 X 10'-6 M after 48 hrs by luciferase reporter gene assay2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Synthesis of novel vitamin K2 analogues with modification at the ω-terminal position and their biological evaluation as potent steroid and xenobiotic receptor (SXR) agonists.
AID1659335Induction of neuronal differentiation of neuronal progenitor cells isolated from embryonic mouse cerebrum assessed as increase in MAP2 mRNA expression at 1 uM by real time PCR analysis2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Study on structure-activity relationship of vitamin K derivatives: Conversion of the naphthoquinone part into another aromatic ring and evaluation of their neuronal differentiation-inducing activity.
AID322666Induction of apoptosis against human MG63 cells after 72 hrs2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Design and synthesis of biologically active analogues of vitamin K2: evaluation of their biological activities with cultured human cell lines.
AID1659336Induction of neuronal differentiation of neuronal progenitor cells isolated from embryonic mouse cerebrum at 1 uM treated every second day for 4 days and measured after 48 hrs by DAPI/MAP2 fluorescent immunostaining based assay2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Study on structure-activity relationship of vitamin K derivatives: Conversion of the naphthoquinone part into another aromatic ring and evaluation of their neuronal differentiation-inducing activity.
AID605758Agonist activity at human SXR transfected in human HepG2 cells coexpressing GAL4 assessed as activation of receptor-mediated CYP3A4 gene transcription at 1 X 10'-6 M after 48 hrs by luciferase reporter gene assay2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Synthesis of novel vitamin K2 analogues with modification at the ω-terminal position and their biological evaluation as potent steroid and xenobiotic receptor (SXR) agonists.
AID1241686Induction of neuronal differentiation in mouse neuronal progenitor cells assessed as relative ratio of expression of Map2/Gfap mRNA at 1 uM treated for every second day for 4 days by RT-PCR analysis2015Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17
Synthetic Small Molecules Derived from Natural Vitamin K Homologues that Induce Selective Neuronal Differentiation of Neuronal Progenitor Cells.
AID608160Agonist activity at SXR/RXR expressed in human HepG2 cells co-transfected with pGL4.10-CYP3A4 vector assessed as induction of CYP3A4 gene expression at 5 x 10'-6 M after 48 hrs by dual-luciferase reporter gene assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Synthesis of new vitamin K analogues as steroid and xenobiotic receptor (SXR) agonists: insights into the biological role of the side chain part of vitamin K.
AID608160Agonist activity at SXR/RXR expressed in human HepG2 cells co-transfected with pGL4.10-CYP3A4 vector assessed as induction of CYP3A4 gene expression at 5 x 10'-6 M after 48 hrs by dual-luciferase reporter gene assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Synthesis of new vitamin K analogues as steroid and xenobiotic receptor (SXR) agonists: insights into the biological role of the side chain part of vitamin K.
AID1659335Induction of neuronal differentiation of neuronal progenitor cells isolated from embryonic mouse cerebrum assessed as increase in MAP2 mRNA expression at 1 uM by real time PCR analysis2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Study on structure-activity relationship of vitamin K derivatives: Conversion of the naphthoquinone part into another aromatic ring and evaluation of their neuronal differentiation-inducing activity.
AID605759Binding affinity to human SXR transfected in human HepG2 cells coexpressing GAL4 assessed as transcriptional activation at 5 X 10'-6 M after 48 hrs by luciferase reporter gene assay2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Synthesis of novel vitamin K2 analogues with modification at the ω-terminal position and their biological evaluation as potent steroid and xenobiotic receptor (SXR) agonists.
AID1659336Induction of neuronal differentiation of neuronal progenitor cells isolated from embryonic mouse cerebrum at 1 uM treated every second day for 4 days and measured after 48 hrs by DAPI/MAP2 fluorescent immunostaining based assay2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Study on structure-activity relationship of vitamin K derivatives: Conversion of the naphthoquinone part into another aromatic ring and evaluation of their neuronal differentiation-inducing activity.
AID608159Agonist activity at human FLAG-tagged SXR ligand binding domain expressed in human HepG2 cells co-transfected with pGVP2-Gal4 vector assessed as induction of CYP3A4 gene expression at 5 x 10'-6 M after 48 hrs by dual-luciferase reporter gene assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Synthesis of new vitamin K analogues as steroid and xenobiotic receptor (SXR) agonists: insights into the biological role of the side chain part of vitamin K.
AID322666Induction of apoptosis against human MG63 cells after 72 hrs2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Design and synthesis of biologically active analogues of vitamin K2: evaluation of their biological activities with cultured human cell lines.
AID1241686Induction of neuronal differentiation in mouse neuronal progenitor cells assessed as relative ratio of expression of Map2/Gfap mRNA at 1 uM treated for every second day for 4 days by RT-PCR analysis2015Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17
Synthetic Small Molecules Derived from Natural Vitamin K Homologues that Induce Selective Neuronal Differentiation of Neuronal Progenitor Cells.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346802Mouse Pregnane X receptor (1I. Vitamin D receptor-like receptors)2003The Journal of biological chemistry, Nov-07, Volume: 278, Issue:45
Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (51)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pharmacokinetics of Omega-3 Fatty Acids Esterified in Monoglycerides, Ethyl Esters, or Triglycerides in Humans [NCT03897660]22 participants (Actual)Interventional2019-03-29Completed
Clinical Study Evaluating the Role of Vitamin K2 as Adjuvant Therapy to Angiotensin Converting Enzyme Inhibitor on Blood Pressure, Proteinuria and Bone Metabolism in Patients With Chronic Kidney Disease [NCT05942053]Phase 444 participants (Anticipated)Interventional2023-07-15Not yet recruiting
Evaluation of Factors II, VII, IX, X, and Proteins C and S, Following High-dose Vitamin K Supplementation [NCT01143831]8 participants (Actual)Interventional2009-11-30Completed
Effects of Vitamin K2 on Recovery From Muscle Damaging Exercise in Young and Older Adults [NCT04676958]80 participants (Actual)Interventional2021-04-01Completed
Comparison of Efficacy of Different Dosages Vitamin K2 [NCT01194778]82 participants (Actual)Interventional2009-10-31Completed
Influence of Vitamin K2 Administration on Vessel Calcification Markers in Patients With Chronic Kidney Disease [NCT01101698]Phase 460 participants (Anticipated)Interventional2009-06-30Recruiting
The Additive Effect of Vitamin K Supplementation and Bisphosphonate on Fracture Risk in Post-menopausal Osteoporosis [NCT01232647]Phase 2/Phase 3105 participants (Actual)Interventional2015-04-30Active, not recruiting
A Phase 2, Double Blind, Randomized, Placebo-controlled Clinical Trial to Investigate the Safety and Effects of Oral Vitamin K2 Supplementation in COVID-19 [NCT04770740]40 participants (Actual)Interventional2021-02-22Completed
Decalcification of the Aortic Valve by Vitamin K2 (Menaquinone-7) [NCT03305536]Phase 2150 participants (Anticipated)Interventional2018-01-02Recruiting
A Randomized, Placebo-controlled, Double Blind Trial to Investigate Whether Vitamin K2 Can Influence Arterial Calcification in Patients With Type 2 Diabetes [NCT02839044]68 participants (Actual)Interventional2016-06-30Completed
The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: A Randomized Controlled Trial [NCT02610933]Phase 4117 participants (Actual)Interventional2015-11-30Completed
Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes [NCT02366481]30 participants (Anticipated)Interventional2015-02-28Active, not recruiting
Comparison of Absorption and Efficacy of 3 Different Menaquinone-7 Delivery Systems; Casein Powder, Arabic Gum Powder, or Linseed Oil [NCT00858767]69 participants (Actual)Interventional2008-10-31Completed
Comparison of Absorption of Vitamin K2 Human Study Gelpell [NCT00742768]16 participants (Actual)Interventional2008-06-30Completed
Clinical Trial on Beneficial Effects of Long Term Menaquinone-7 (Vitamin K2) Intake by Postmenopausal Women [NCT00642551]240 participants (Actual)Interventional2008-03-31Completed
Antioxidant and Immune Effects of Vitamin K2 - the ProteK2t Study [NCT05675163]60 participants (Actual)Interventional2022-11-15Completed
Effects of Omega-3 Fatty Acids and Menaquinone-7 on Thrombotic Tendency [NCT00732576]57 participants (Actual)Interventional2008-01-31Completed
Risk Factors for Vascular Calcifications in Hemodialysis Patients: to What Extent is Vitamin K2 Deficiency Involved? [NCT02876354]Phase 450 participants (Actual)Interventional2016-08-31Completed
Pilot Study of Vitamin K2 (MK-7) and Vitamin D3 Supplementation and the Effects on PASC Symptomatology and Inflammatory Biomarkers [NCT05356936]150 participants (Anticipated)Interventional2022-06-01Active, not recruiting
Vitamin K and Glucose Metabolism in Children at Risk for Diabetes [NCT01972113]30 participants (Anticipated)Interventional2013-09-30Recruiting
Bicuspid Aortic Valve Stenosis and the Effect of vItamin K2 on Calciummetabolism on 18F-NaF PET/MRI (BASIK2): a Pilot Study [NCT02917525]Phase 244 participants (Anticipated)Interventional2016-08-31Recruiting
Short-Term Menatetrenone Therapy Increases Gamma-Carboxylation Of Osteocalcin With A Moderate Increase Of Bone Turnover In Postmenopausal Osteoporosis: A Randomized Prospective Study [NCT00548509]Phase 4131 participants (Actual)Interventional2002-02-01Completed
The Effects of Vitamin K2 Supplementation on the Progression of Coronary Artery Calcification [NCT01002157]180 participants (Actual)Interventional2011-10-31Active, not recruiting
Effect of Vitamin K2 Supplementation and Its Association With Osteocalcin Serum Levels, Leptin, Th1/Th2 Cytokine Profile, and Cardiovascular Risk in Young Mexican Adults With Overweight and Obesity [NCT05995522]51 participants (Anticipated)Interventional2023-09-01Not yet recruiting
A Randomized, Placebo-Controlled, Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma [NCT00165633]Phase 2/Phase 3540 participants (Anticipated)Interventional2004-03-31Terminated
The Effects of Menaquinone-7 Supplementation in Patients With Severe Coronary Calcifications [NCT05500443]400 participants (Anticipated)Interventional2023-02-08Recruiting
Safety Study of Vitamin K2 During Anticoagulation in Human Volunteers [NCT00512928]20 participants (Actual)Interventional2007-09-30Completed
Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk [NCT02959762]30 participants (Anticipated)Interventional2016-10-31Active, not recruiting
The VITAKIDS-Study: The Effect of Vitamin K Supplementation on Osteocalcin Carboxylation in Healthy Children [NCT00402974]55 participants (Actual)Interventional2007-01-31Completed
Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients: A Prospective, Randomized Placebo-controlled Double Blind Trial [NCT02976246]Phase 4123 participants (Actual)Interventional2016-11-30Completed
Study of the Effect of Food Vitamin K2 Intake in Association With a Fermented Dairy Product on Patients Treated With Vitamin K Antagonist (VKA) [NCT01533441]Phase 250 participants (Actual)Interventional2012-02-29Completed
Role of Vitamin K2 in the Reduction of the Calcium Content at the Level of the Carotid Bifurcation in Patients With Subcritical Lesions [NCT02970084]60 participants (Actual)Interventional2016-11-30Completed
Effects Vitamin K2 on Muscle Mass and Function in People With Muscle Weakness and Type 2 Diabetes [NCT05375630]150 participants (Anticipated)Interventional2022-03-21Recruiting
The Impact of Vitamin K2 and Inactive Vitamin D Supplementation on Vascular Calcification in Pediatric Patients on Regular Hemodialysis [NCT04145492]Phase 2/Phase 360 participants (Anticipated)Interventional2019-09-01Recruiting
Effect of Vitamin K2 Supplementation on Vascular Calcification in Hemodialysis Patients: a Controlled Randomized Trial. [NCT04539418]Phase 459 participants (Actual)Interventional2016-12-01Completed
Comparison of Effects of Nutritional Doses Vitamin K1 and K2 on Carboxylation [NCT01638182]81 participants (Actual)Interventional2011-03-31Completed
Dietary Supplements to Reduce Symptom Severity and Duration in People With SARS-CoV-2: A Randomized, Double Blind, Placebo Controlled Clinical Trial [NCT04780061]Phase 390 participants (Actual)Interventional2021-07-12Terminated(stopped due to Public PCR testing stopped in Ontario)
Comparison of Pharmacokinetics of Omega-3 Fatty Acid Supplements in Monoacylglycerol or Ethyl Ester in Humans: a Randomized Controlled Trial. [NCT04382027]20 participants (Actual)Interventional2010-11-11Completed
Phase 2 Study Randomized Placebo Controlled With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis [NCT01923012]Phase 2200 participants (Anticipated)Interventional2013-09-30Not yet recruiting
Novel Health Effects of Vitamin K: a Placebo-controlled Randomized Trial in the General Population (InterVitaminK) [NCT05259046]450 participants (Anticipated)Interventional2022-06-21Recruiting
Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients (Vita-K 'n' CKD Study) [NCT03311321]60 participants (Anticipated)Interventional2017-09-13Recruiting
Inhibition of Aortic Valve Calcification Through the Carboxylation Mechanism of Matrix Gla Protein (MGP), Following Administration of Vitamin K2 (Menaquinone-7). Correlation With Mitral Annulus and Ascending Aorta Calcification. [NCT04429035]200 participants (Anticipated)Interventional2019-09-23Recruiting
Comparative Study Evaluating the Effect of the Administration of Vitamin K1 Versus Vitamin K2 on Vascular Calcification in Dialysis Patients [NCT04477811]Phase 2/Phase 340 participants (Actual)Interventional2020-07-25Completed
Intervention Study on the Effect of Vitamin K2 (Menaquinone-7) Supplementation on the Vascular Stiffness in Subjects With Poor Vitamin K-status [NCT02404519]240 participants (Actual)Interventional2016-01-31Active, not recruiting
Treatment to Reduce Vascular Calcification in Hemodialysis Patients Using Vitamin K (Trevasc-HDK): A Study Protocol for a Randomized Controlled Trial [NCT02870829]Phase 2178 participants (Actual)Interventional2016-07-31Completed
Randomized Prospective Open Interventional Multi-centre Study on Finding the Optimal Dose of Vitamin K2 Supplements for Hemodialysis Patients [NCT01675206]Phase 3165 participants (Actual)Interventional2011-05-31Completed
The Effects of Menaquinone-7 Supplementation in Patients With Aortic Valves Calcification [NCT03243890]389 participants (Actual)Interventional2018-01-12Completed
Effect of Vitamin K2 in the Treatment of Nocturnal Leg Cramps in Older Population: Study Protocol of a Randomized, Double-blind, Controlled Trial [NCT05547750]200 participants (Anticipated)Interventional2022-10-01Enrolling by invitation
Efficacy of Vitamin K2 Supplementation in Adult Episodic Migraine [NCT05943457]160 participants (Anticipated)Interventional2023-09-30Not yet recruiting
Effects of Vitamin K2 Supplements on Recovery of Lower Limb Muscle Function After Ankle Injury in Adults [NCT05161975]60 participants (Anticipated)Interventional2021-12-15Not yet recruiting
Vitamin K2 Supplementation and Effect on Arterial Stiffness Progression in the Renal Transplant Population [NCT02517580]Phase 260 participants (Actual)Interventional2015-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02517580 (1) [back to overview]Reduction From Baseline in Carotid-femoral Pulse Wave Velocity at 8 Weeks

Reduction From Baseline in Carotid-femoral Pulse Wave Velocity at 8 Weeks

(NCT02517580)
Timeframe: 8 weeks

Interventionm/s (Mean)
Vitamin K2 (MK7)-1.4

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
vitamin k 3
Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.		2.25101,4-naphthoquinones;
vitamin K		angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
ubiquinone q2
Ubiquinone Q2: interacts with iron atom to form acceptor quinone complex; RN given refers to cpd with unspecified isomeric designation		2.2510ubiquinones
menatetrenone
menaquinone-4 : A menaquinone whose side-chain contains 4 isoprene units in an all-trans-configuration.		2.7530menaquinoneanti-inflammatory agent;
antioxidant;
bone density conservation agent;
human metabolite;
neuroprotective agent
vitamin k 1
Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.. phylloquinone : A member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones.		2.0610phylloquinones;
vitamin K		cofactor;
human metabolite;
plant metabolite
ubiquinone q3
[no description available]		2.2510
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.4720cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
vitamin k 3
Vitamin K 3: A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.		2.25101,4-naphthoquinones;
vitamin K		angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical
ubiquinone q2
Ubiquinone Q2: interacts with iron atom to form acceptor quinone complex; RN given refers to cpd with unspecified isomeric designation		2.2510ubiquinones
menatetrenone
menaquinone-4 : A menaquinone whose side-chain contains 4 isoprene units in an all-trans-configuration.		2.7530menaquinoneanti-inflammatory agent;
antioxidant;
bone density conservation agent;
human metabolite;
neuroprotective agent
vitamin k 1
Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.. phylloquinone : A member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones.		2.0610phylloquinones;
vitamin K		cofactor;
human metabolite;
plant metabolite
ubiquinone q3
[no description available]		2.2510
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.4720cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Osteogenic Sarcoma
[description not available]		02.0110
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		02.0110
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310